DrugPatentWatch Database Preview
Eli Lilly And Co Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Eli Lilly And Co
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | EMGALITY | galcanezumab-gnlm | INJECTABLE;INJECTION | 761063 | 001 | 2018-09-27 | RX | |||||
| Eli Lilly And Co | LARTRUVO | olaratumab | INJECTABLE; INJECTION | 761038 | 001 | 2019-07-10 | 9,775,915 | President and Fellows of Harvard College (Cambridge, MA) | 2032-11-26 | RX | Orphan | search |
| Eli Lilly And Co | LARTRUVO | olaratumab | INJECTABLE; INJECTION | 761038 | 001 | 2019-07-10 | 9,534,058 | ABBVIE STEMCENTRX LLC (North Chicago, IL) | 2032-02-08 | RX | Orphan | search |
| Eli Lilly And Co | LARTRUVO | olaratumab | INJECTABLE; INJECTION | 761038 | 001 | 2019-07-10 | 9,447,431 | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | Orphan | search |
| Eli Lilly And Co | LARTRUVO | olaratumab | INJECTABLE; INJECTION | 761038 | 001 | 2019-07-10 | 9,388,243 | SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) | 2033-05-29 | RX | Orphan | search |
| Eli Lilly And Co | LARTRUVO | olaratumab | INJECTABLE; INJECTION | 761038 | 001 | 2019-07-10 | 9,364,567 | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
